Psoriatic arthritis (PsA) is a complex inflammatory disorder that affects up to 30% of psoriasis patients. Its heterogeneous clinical manifestations and lack of standardized diagnostic criteria pose significant challenges for therapy development. Although targeted therapies have advanced in recent years, the unclear pathogenesis and patient variability highlight the need for robust preclinical models. To address this, we established two inducible PsA mouse models designed to support drug efficacy testing and accelerate therapeutic innovation.